These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20886391)

  • 1. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.
    Raje N; Vallet S
    Curr Opin Mol Ther; 2010 Oct; 12(5):586-97. PubMed ID: 20886391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
    Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
    Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activin receptor antagonists for cancer-related anemia and bone disease.
    Fields SZ; Parshad S; Anne M; Raftopoulos H; Alexander MJ; Sherman ML; Laadem A; Sung V; Terpos E
    Expert Opin Investig Drugs; 2013 Jan; 22(1):87-101. PubMed ID: 23127248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
    Sherman ML; Borgstein NG; Mook L; Wilson D; Yang Y; Chen N; Kumar R; Kim K; Laadem A
    J Clin Pharmacol; 2013 Nov; 53(11):1121-30. PubMed ID: 23939631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.
    Walpurgis K; Thomas A; Vogel M; Reichel C; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1152-1161. PubMed ID: 27649383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
    Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
    Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
    Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
    J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-based strategies for the detection of Luspatercept (ACE-536) in human serum.
    Reichel C; Gmeiner G; Thevis M
    Drug Test Anal; 2017 Nov; 9(11-12):1721-1730. PubMed ID: 28929587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
    Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
    Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of soluble recombinant TGF-beta type II receptor fused with the Fc portion of human IgG1 (sTbetaRII-Fc) in NS0 cells.
    Kwiatkowska EP; Kazimierczak U; Mackiewicz A; Kowalczyk DW
    Acta Biochim Pol; 2006; 53(2):361-9. PubMed ID: 16733563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.
    Ruckle J; Jacobs M; Kramer W; Pearsall AE; Kumar R; Underwood KW; Seehra J; Yang Y; Condon CH; Sherman ML
    J Bone Miner Res; 2009 Apr; 24(4):744-52. PubMed ID: 19049340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
    de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
    Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.
    Hibbitts S
    Curr Opin Mol Ther; 2010 Oct; 12(5):598-606. PubMed ID: 20886392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Sotatercept (ACE-011) in human serum by SAR-PAGE and western single blotting.
    Reichel C; Farmer L; Gmeiner G; Walpurgis K; Thevis M
    Drug Test Anal; 2018 Jun; 10(6):927-937. PubMed ID: 29193906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luspatercept: First Approval.
    Markham A
    Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.
    Zhang J; Dai J; Yao Z; Lu Y; Dougall W; Keller ET
    Cancer Res; 2003 Nov; 63(22):7883-90. PubMed ID: 14633717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.